Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

SEHK:874 Lagerbericht

Marktkapitalisierung: HK$53.0b

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Guangzhou Baiyunshan Pharmaceutical Holdings Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Hong Li

Geschäftsführender

CN¥1.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts30.6%
Amtszeit als Geschäftsführer6.9yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.8yrs

Jüngste Management Updates

The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

May 23
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

May 26
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

Recent updates

The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

May 23
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

May 13
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Mar 08
Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Feb 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Jan 25
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

Jan 09
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Nov 28
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 15
A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Oct 19
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Oct 03
Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Aug 15
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Aug 02
Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Jul 02
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jun 01
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

May 01
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Mar 28
The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Jan 23
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Dec 24
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 24
Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Nov 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Aug 02
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

May 30
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Apr 29
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Apr 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Jan 09
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Oct 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jul 12
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

May 26
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Apr 30
How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

Apr 08
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Mar 25
These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 02
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Feb 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Jan 26
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Jan 06
Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Dec 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 26
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Hong Li im Vergleich zu den Einnahmen von Guangzhou Baiyunshan Pharmaceutical Holdings verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥2mCN¥471k

CN¥4b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥2mCN¥460k

CN¥4b

Sep 30 2022n/an/a

CN¥4b

Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥2mCN¥456k

CN¥4b

Sep 30 2021n/an/a

CN¥4b

Jun 30 2021n/an/a

CN¥4b

Mar 31 2021n/an/a

CN¥3b

Dec 31 2020CN¥1mCN¥442k

CN¥3b

Sep 30 2020n/an/a

CN¥3b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥3b

Dec 31 2019CN¥1mCN¥428k

CN¥3b

Sep 30 2019n/an/a

CN¥3b

Jun 30 2019n/an/a

CN¥3b

Mar 31 2019n/an/a

CN¥4b

Dec 31 2018CN¥1mCN¥382k

CN¥3b

Vergütung im Vergleich zum Markt: HongDie Gesamtvergütung ($USD212.49K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD916.56K).

Entschädigung vs. Einkommen: HongDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Hong Li (56 yo)

6.9yrs

Amtszeit

CN¥1,539,030

Vergütung

Mr. Hong Li has been General Manager at Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited since June 23, 2017 and serves as its Executive Director since June 22, 2018. Mr. Li started his career...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Chuyuan Li
Executive Chairman13.9yrskeine Datenkeine Daten
Hong Li
GM & Executive Director6.9yrsCN¥1.54mkeine Daten
Ning Cheng
Executive Vice Chairman11.7yrskeine Datenkeine Daten
Jun Yang
Executive Vice Chairman4.3yrskeine Datenkeine Daten
Changhai Wu
Deputy GM & Executive Director9.3yrsCN¥1.57mkeine Daten
Juyan Liu
Executive Directorno datakeine Datenkeine Daten
Zhang Chunbo
Executive Director8.3yrsCN¥1.56mkeine Daten
Haoshan Zheng
Deputy GM & Director of Business Administration Department4.8yrsCN¥1.41mkeine Daten
Xuezhen Huang
Secretary7.1yrsCN¥1.24mkeine Daten

7.0yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 874 ist erfahren und erfahren (durchschnittliche Amtszeit: 7 Jahre).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Chuyuan Li
Executive Chairman13.9yrskeine Datenkeine Daten
Hong Li
GM & Executive Director5.9yrsCN¥1.54mkeine Daten
Ning Cheng
Executive Vice Chairman11.7yrskeine Datenkeine Daten
Jun Yang
Executive Vice Chairman4.3yrskeine Datenkeine Daten
Changhai Wu
Deputy GM & Executive Director13.9yrsCN¥1.57mkeine Daten
Juyan Liu
Executive Director10.3yrskeine Datenkeine Daten
Zhang Chunbo
Executive Director4.9yrsCN¥1.56mkeine Daten
Lung Tak Wong
Independent Non-Executive Directorless than a yearCN¥50.00kkeine Daten
Ruiyu Cai
Chairman of the Supervisory Board4.7yrskeine Datenkeine Daten
Yajin Chen
Independent Non-Executive Director3.9yrsCN¥120.00kkeine Daten
Min Huang
Independent Non-Executive Director3.9yrsCN¥120.00kkeine Daten
Sun Baoqing
Independent Non-Executive Directorless than a yearkeine Datenkeine Daten

4.8yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrener Vorstand: 874Die Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).